Literature DB >> 3261449

Albumin prevents erythrocyte crenation in patients undergoing extracorporeal circulation.

T Kamada1, D E McMillan, J J Sternlieb, V O Björk, S Otsuji.   

Abstract

Free fatty acid-induced massive erythrocyte crenation has been reported in patients undergoing extracorporeal circulation (EC), suggesting that the crenated cells impair microcirculatory flow and tissue oxygenation during and after the operation. Effect of albumin administration on erythrocyte crenation was examined in 18 patients undergoing coronary bypass operation: 9 patients were given 25 g and another 9 patients were given 50 g of human albumin as a part of the priming solution. Erythrocyte crenation was almost completely prevented in the patients given 50 g albumin. Crenated erythrocytes during EC were 3.6 +/- 2.3% (mean +/- SD) of all erythrocytes and 2.8 +/- 3.7% after EC. This was significantly lower than in patients without albumin administration (63.4 +/- 34.0% during EC and 28.6 +/- 33.3% after EC, n = 20). But the effect was less striking in the patients given 25 g albumin, 32.4 +/- 39.1% during and 28.3 +/- 40.8% after EC. Maintaining an adequate level of plasma albumin is important in preventing erythrocyte crenation during EC, improving microcirculatory flow in patients undergoing open heart surgery.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261449     DOI: 10.3109/14017438809105949

Source DB:  PubMed          Journal:  Scand J Thorac Cardiovasc Surg        ISSN: 0036-5580


  2 in total

Review 1.  Mechanical blood trauma in assisted circulation: sublethal RBC damage preceding hemolysis.

Authors:  Salim E Olia; Timothy M Maul; James F Antaki; Marina V Kameneva
Journal:  Int J Artif Organs       Date:  2016-03-30       Impact factor: 1.595

2.  Effect of 6% hydroxyethyl starch 130/0.4 as a priming solution on coagulation and inflammation following complex heart surgery.

Authors:  Jang-Eun Cho; Jae-Kwang Shim; Jong-Wook Song; Jong-Won Song; Hye-Won Lee; Dong-Hwan Kim; Young-Lan Kwak
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.